Draft European Medicines Agency Strategy 2028: Enhancing Accessibility and Innovation

By João L. Carapinha

October 21, 2024

The draft European Medicines Agencies Network Strategy to 2028 is a timely update to the previous strategy covering 2021 to 2025 (EMANS 2025). This new strategy aims to address the evolving landscape of medicines regulation while ensuring the accessibility of safe and effective medicines within the EU.

Background and Context

The EMA developed the original strategy (EMANS 2025) in response to the rapid changes in the medicines landscape, particularly during the COVID-19 pandemic. Since then, substantial shifts have occurred in both regulatory and technological spheres. This includes new EU legislation for public health emergencies and the establishment of the Directorate-General for Health Emergency Preparedness and Response (DG HERA).

Key Focus Areas

The draft strategy to 2028 is organized around six strategic focus areas:

  1. Accessibility: The primary goal is to facilitate pathways for access to medicines through healthcare systems in the EU. This will ensure efficient and predictable access for patients and veterinary medicine users.
  2. Leveraging Data, Digitalisation, and Artificial Intelligence: The plan emphasizes making decisions more effective and optimizing processes by integrating technological advancements, especially in AI and digitalisation.
  3. Regulatory Science, Innovation, and Competitiveness: A core focus is to foster a regulatory and research environment that enhances innovation and competitiveness within the EU’s healthcare sector. This will help accelerate the translation of new ideas into market-ready medicines.
  4. Antimicrobial Resistance and Other Health Threats: There’s a strong commitment to prepare the EU for potential health threats. This includes antimicrobial resistance, ensuring that the network is ready to respond to public health emergencies.
  5. Availability and Supply: The strategy aims to bolster the availability of medicines to protect public and animal health. By addressing supply-chain challenges, it seeks to ensure a steady supply of essential medicines.
  6. Sustainability of the Network: Ensuring that the network possesses the necessary resources is crucial. This support will enhance the scientific and regulatory decision-making processes, maintaining operational excellence and sustainability.

Consultation and Implementation

An eight-week public consultation for the draft strategy is open until 30 November 2024. The EMA encourages stakeholders to provide feedback via an online questionnaire. Following this consultation, the EMA and will refine the strategy, aiming for adoption by March 2025. Th EMA will implement the finalized strategy through respective multi-annual work plans.

Additional Resources

The EMA published a reflection paper to aid in the consultation process. It offers insights into the considerations and discussions that informed the draft strategy.

In summary, the draft European Medicines Agencies Network Strategy to 2028 is designed to align the regulatory framework with the dynamic landscape of medicine regulations. By leveraging new technologies and addressing health threats, the strategy ensures that the continued accessibility of safe and effective medicines remains a priority across the EU.

Reference url

Recent Posts

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

Tolebrutinib MS analysis
          

Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS

💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?

A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.

Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.

#SyenzaNews #HealthEconomics #MarketAccess

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.